Publications by authors named "Jeongok Lee"
Article Synopsis
- A phase II clinical trial was conducted to assess the effectiveness of imatinib in treating PDGFRA/B-negative hypereosinophilic syndromes (HES), with 32 patients receiving doses ranging from 100-400 mg daily.
- The study found a haematological response rate of 46.9%, with 18.8% achieving a complete response, and the median time to this response was 1.5 months.
- Genetic analysis revealed that while there were no differences in non-silent mutations between responders and non-responders, specific gene fusions were linked to sustained responses, suggesting imatinib could be a viable treatment alongside proper biomarkers.
Article Synopsis
- - The study investigates the effectiveness and safety of direct oral anticoagulants (DOACs) in patients with myeloproliferative neoplasms (MPNs), highlighting concerns regarding thrombosis and bleeding risks.
- - A nationwide cohort analysis of 368 MPN patients revealed that 62.8% were on DOACs for atrial fibrillation, with a median follow-up of 22.3 months showing thrombosis and bleeding rates of 11.1% and 3.7%, respectively.
- - Key factors increasing thrombosis risk included high CHA2DS2-VASc scores and the use of concomitant antiplatelet and cytoreductive therapies, but no significant predictors were found
Purpose: Some studies suggest that TP53 mutations are associated with the response to immune checkpoint inhibitors (ICI) in patients with non-small cell lung cancer (NSCLC) and also contribute to sex disparities in several cancers. Thus, we hypothesized that TP53 mutations might serve as sex-dependent genomic biomarkers of ICI treatment response in patients with NSCLC.
Materials And Methods: Clinical data of 100 patients with metastatic NSCLC treated with ICI monotherapy at Seoul National University Bundang Hospital (SNUBH) were retrospectively reviewed.
Background: Multiple myeloma (MM) patients are at risk of skeletal-related events (SREs) like spinal cord compression, pathologic fractures, bone surgery, and radiation to bone. Real-world data regarding SREs in MM are limited.
Methods: We conducted a large, retrospective, nationwide cohort study using the Korean Health Insurance Review and Assessment Service (HIRA) database from 2007 to 2018.
Article Synopsis
- Erythrocytosis is linked to various factors, with many JAK2-unmutated cases remaining undiagnosed; this study focused on understanding these cases better.
- A total of 117 patients with JAK2-unmutated erythrocytosis were analyzed, revealing median hemoglobin levels of 17.9 g/dL and thrombotic events in 14.5% of patients.
- Genetic testing showed that 36.4% of patients had somatic mutations and 33.3% had germline mutations, but most variants' clinical significance is still unclear, highlighting the need for comprehensive diagnostic methods to determine the causes of erythrocytosis.
Article Synopsis
- * The primary outcome, objective response rate (ORR), was 54.5% with a complete remission (CR) rate of 31.8%, indicating successful performance against the disease in a group of 66 enrolled patients.
- * Adverse events were mostly manageable, with neutropenia being the most common; certain genetic markers such as MYD88 mutations showed promise for predicting treatment response, pointing to potential personalized therapy
Article Synopsis
- Brentuximab vedotin (BV) is an antibody-drug conjugate approved in Korea for treating relapsed or refractory Hodgkin lymphoma (HL), anaplastic large-cell lymphoma (ALCL), and cutaneous T-cell lymphomas, but there's limited real-world data on its effectiveness.
- In a study involving 85 patients, BV showed high efficacy rates with an objective response rate (ORR) of 85.4% for HL, 88% for ALCL, and 92% for mycosis fungoides (MF), with median progression-free survival times of approximately 23.6 months for HL, 29.0 months for ALCL, and 16.7 months for MF. *
Purpose: Programmed death-1 blockade with pembrolizumab has shown promising activity in relapsed/refractory (R/R) extranodal natural killer/T-cell lymphoma (NKTCL), but studies are limited, with small patient numbers.
Materials And Methods: Thirteen institutes involved with the Consortium for Improving Survival of Lymphoma, a Korean lymphoma study group, collected the clinical data of 59 patients treated with pembrolizumab as salvage therapy between 2016 and 2022.
Results: The median age of the patients was 60 years (range, 22 to 87 years), and 76.
Article Synopsis
- A study examined the thromboembolic risk (VTE and ATE) in patients with recurrent/metastatic colorectal cancer treated with cetuximab plus chemotherapy compared to those receiving chemotherapy alone.
- Using nationwide claims data from South Korea (2013-2020), researchers found that patients taking cetuximab had a significantly higher incidence of thromboembolic events, with 5.62% experiencing any event compared to 3.58% for chemotherapy alone.
- The study concluded that cetuximab combined with chemotherapy substantially increased the risk of thromboembolic events, prompting the need for further research into the mechanisms behind this association.
Purpose: Despite the recent success of Bruton's tyrosine kinase (BTK) inhibitors for the treatment of Waldenstrom macroglobulinemia (WM), their indefinite treatment duration ultimately tantamount to substantial financial and emotional burden. On the other hand, fixed duration of proteasome inhibitors (PI) have shown rapid and reasonable response in WM treatment. Despite the well-known synergism between PI and immunomodulatory drugs (IMiD), there is no trials evaluating such combination in WM.
View Article and Find Full Text PDFArticle Synopsis
- * The results showed that patients receiving auto-SCT had significantly better overall survival rates compared to those receiving allo-SCT, but there was no notable difference in progression-free survival.
- * Auto-SCT was particularly beneficial for patients in complete remission, while allo-SCT offered better progression-free survival for those with partial remission or relapsed disease, despite a high early mortality rate associated with allo-SCT.
Article Synopsis
- Chronic hepatitis B (CHB) can increase the risk of a type of cancer called non-Hodgkin lymphoma (NHL).
- This study looked at two groups of lymphoma patients: those with CHB who got antiviral treatment and those without CHB.
- Results showed that CHB patients who received antiviral treatment lived longer and had better progress in their cancer treatment compared to those without hepatitis B.
Introduction: This prospective study aimed to investigate the efficacy and safety of preemptive antiviral therapy with tenofovir disoproxil fumarate (TDF) for HBsAg-positive patients with newly diagnosed diffuse large B-cell lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy.
Methods: We enrolled 73 patients from 20 institutions. The primary end point was the absolute risk of hepatitis B virus (HBV)-related hepatitis during preemptive TDF therapy and for 24 weeks after withdrawal from TDF.
Peli1 is an E3 ubiquitin ligase involving lymphomagenesis by lysine 63 ubiquitination-mediated stabilization of Bcl-6 with in diffuse large B-cell lymphoma (DLBCL). We categorized nuclear expression of Peli1 according to Bcl-6 status by immunohistochemistry in DLBCL (n=100), and analyzed clinicopathologic association with prognosis. We established Bcl-6/Peli1 risk model composed of high risk (Bcl-6+/Peli1+ or Bcl-6-/Peli1-; n=64) and low risk (Bcl-6+/Peli1- or Bcl-6-/Peli1+; n=36).
View Article and Find Full Text PDFBACKGROUNDChronotherapy is a drug intervention at specific times of the day to optimize efficacy and minimize adverse effects. Its value in hematologic malignancy remains to be explored, in particular in adult patients.METHODSWe performed chronotherapeutic analysis using 2 cohorts of patients with diffuse large B cell lymphoma (DLBCL) undergoing chemotherapy with a dichotomized schedule (morning or afternoon).
View Article and Find Full Text PDFNodal peripheral T-cell lymphoma (PTCL) is a heterogeneous category including angioimmunoblastic T-cell lymphoma (AITL), PTCL of follicular helper T-cell (Tfh) phenotype (PTCL-Tfh), and PTCL, not otherwise specified (PTCL-NOS). We explored Tfh marker profiles in nodal PTCL. Nodal PTCLs (n = 129) were reclassified into AITL (58%; 75/129), PTCL-Tfh (26%; 34/129), and PTCL-NOS (16%; 20/129).
View Article and Find Full Text PDFBackground/aim: The combination of bendamustine and rituximab (BR) is highly effective in both treatment-naïve and relapsed or refractory mantle cell lymphoma (MCL). Due to the rarity of MCL and limited accessibility of BR, clinical outcome from BR in the routine clinical practice in Korean patients are limited.
Patients And Methods: To evaluate the real-world outcomes of BR treatment for MCL in Korea, medical records from 37 patients were retrospectively analyzed.
The effect of metformin or dipeptidyl peptidase 4 inhibitors on clinical outcomes in metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.
Thorac Cancer
January 2023
Background: Preclinical data have shown the immunomodulatory effects of metformin and dipeptidyl peptidase 4 (DPP4) inhibitors in patients with diabetes. However, its clinical impact remains unclear in lung cancer.
Methods: Between 2017 and 2021, 466 patients received ICI monotherapy.
Dasatinib, a tyrosine kinase inhibitor, is usually prescribed for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. However, some patients may develop an intolerance to this drug over the years. Among various toxicities related to dasatinib, dasatinib-associated interstitial pneumonitis is not reported frequently in the literature yet.
View Article and Find Full Text PDFPurpose: Acute palliative care units (APCUs) are inpatient services in tertiary hospitals that provide intensive symptom management and assist in hospital discharge for transitions to hospice care. We aimed to analyze the clinical outcomes of operating an APCU at a comprehensive cancer center.
Patients And Methods: We retrospectively reviewed the medical records of 1,440 consecutive patients admitted to the APCU and analyzed demographic and clinical information, discharge outcomes, symptom assessments using the Edmonton Symptom Assessment System, spiritual distress, and financial distress.
Vemurafenib, an oral BRAF inhibitor, has demonstrated high response rates in relapsed/refractory (R/R) hairy cell leukemia (HCL). However, little is known about long-term outcomes and response to retreatment. Herein, we report the results of 36 patients with R/R HCL treated with vemurafenib from the United States arm of the phase 2 clinical trial (NCT01711632).
View Article and Find Full Text PDFSystemic mastocytosis with associated hematological neoplasm (SM-AHN) poses diagnostic challenges because of the coexistence of atypical mast cell proliferation and hematological neoplasms. We assessed the presence of SM-AHN in patients with acute myeloid leukemia (AML) with from 2014 to 2020. Bone marrow (BM) samples were evaluated for mast cell aggregates using CD117 and CD25 immunohistochemical (IHC) staining.
View Article and Find Full Text PDFObjectives: This study investigated the treatment pattern and the rate of bleeding complications in real-world practice in cancer-associated venous thromboembolism (CT) patients.
Methods: We used the Korean Health Insurance Review and Assessment Service database (2014-2018). Among patients with venous thromboembolism, patients with concomitant malignancy diagnostic codes were categorized as CT, while all others were categorized as non-CT.